JAZZ Jazz Pharmaceuticals plc

Price (delayed)

$167.71

Market cap

$9.34B

P/E Ratio

51.76

Dividend/share

N/A

EPS

$3.24

Enterprise value

$10.83B

Sector: Healthcare
Industry: Biotechnology

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights

The revenue has grown by 11% YoY and by 2.9% from the previous quarter
The gross profit has grown by 11% YoY and by 2.5% from the previous quarter
Jazz Pharmaceuticals's net income has shrunk by 71% YoY but it has increased by 34% QoQ
The company's EPS has shrunk by 69% YoY but it rose by 37% QoQ
The P/E is 134% higher than the 5-year quarterly average of 22.1 and 63% higher than the last 4 quarters average of 31.8
The company's debt rose by 27% YoY

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
55.71M
Market cap
$9.34B
Enterprise value
$10.83B
Valuations
Price to earnings (P/E)
51.76
Price to book (P/B)
2.75
Price to sales (P/S)
4.09
EV/EBIT
42.02
EV/EBITDA
16.86
EV/Sales
4.75
Earnings
Revenue
$2.28B
EBIT
$257.8M
EBITDA
$642.33M
Free cash flow
$797.36M
Per share
EPS
$3.24
Free cash flow per share
$14.36
Book value per share
$60.9
Revenue per share
$41.04
TBVPS
$56.06
Balance sheet
Total assets
$6.29B
Total liabilities
$2.91B
Debt
$2.23B
Equity
$3.38B
Working capital
$1.91B
Liquidity
Debt to equity
0.66
Current ratio
3.98
Quick ratio
3.55
Net debt/EBITDA
2.32
Margins
EBITDA margin
28.2%
Gross margin
94.1%
Net margin
7.9%
Operating margin
11.7%
Efficiency
Return on assets
3.1%
Return on equity
5.8%
Return on invested capital
7.6%
Return on capital employed
4.6%
Return on sales
11.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
1.15%
1 week
3.91%
1 month
9.92%
1 year
9.8%
YTD
1.61%
QTD
1.61%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$2.28B
Gross profit
$2.15B
Operating income
$265.9M
Net income
$179.19M
Gross margin
94.1%
Net margin
7.9%
The company's net margin has shrunk by 73% YoY but it rose by 32% QoQ
Jazz Pharmaceuticals's net income has shrunk by 71% YoY but it has increased by 34% QoQ
JAZZ's operating margin has dropped by 63% year-on-year but it is up by 29% since the previous quarter
The operating income has dropped by 59% year-on-year but it rose by 31% since the previous quarter

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
51.76
P/B
2.75
P/S
4.09
EV/EBIT
42.02
EV/EBITDA
16.86
EV/Sales
4.75
The P/E is 134% higher than the 5-year quarterly average of 22.1 and 63% higher than the last 4 quarters average of 31.8
The company's EPS has shrunk by 69% YoY but it rose by 37% QoQ
The price to book (P/B) is 25% higher than the last 4 quarters average of 2.2 but 17% lower than the 5-year quarterly average of 3.3
Jazz Pharmaceuticals's equity has increased by 11% YoY and by 7% from the previous quarter
The price to sales (P/S) is 28% more than the last 4 quarters average of 3.2 but 13% less than the 5-year quarterly average of 4.7
The revenue has grown by 11% YoY and by 2.9% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The company's return on assets has shrunk by 73% YoY but it rose by 29% QoQ
The return on equity has dropped by 73% year-on-year but it has increased by 32% since the previous quarter
JAZZ's ROIC has shrunk by 70% YoY but it is up by 19% QoQ
The company's return on sales has shrunk by 64% YoY but it rose by 30% QoQ

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 116% greater than the total liabilities
The company's current ratio fell by 29% QoQ but it rose by 2.3% YoY
Jazz Pharmaceuticals's quick ratio has decreased by 29% from the previous quarter but it has increased by 3.8% YoY
The company's debt is 34% lower than its equity
Jazz Pharmaceuticals's debt to equity has increased by 14% YoY but it has decreased by 8% QoQ
Jazz Pharmaceuticals's equity has increased by 11% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.